Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases. (Q38029235)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828717%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828717%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828717%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

D A Katzka

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828717%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

M Camilleri

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828717%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

language of work or name

English

0 references

publication date

25 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828717%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828717%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828717%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828717%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

306-320

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828717%20AND%20SRC:MED&resulttype=core&format=json

Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study

8 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Prevalence of eosinophilic esophagitis in adults with food bolus obstruction of the esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Eosinophilic esophagitis: rapidly advancing insights.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Glucocorticoid-regulated genes in eosinophilic esophagitis: a role for FKBP51.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: current status and recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Personalized cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Chronic treatment of Ménétrier's disease with Erbitux: clinical efficacy and insight into pathophysiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Efficacy of Cetuximab in the Treatment of Menetrier's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Maintenance of parenteral nutrition volume reduction, without weight loss, after stopping teduglutide in a subset of patients with short bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Anti-interleukin-12 antibody for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Influence of ghrelin on the gastric accommodation reflex and on meal-induced satiety in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

5-HT4 receptor agonists: similar but not the same

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

A placebo-controlled trial of prucalopride for severe chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

NHERF family and NHE3 regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Efficacy of linaclotide for patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Effect of the α2δ ligand, pregabalin, on colonic sensory and motor functions in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Advances in celiac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

7 January 2021

Roles of ZO-1 and epidermal growth factor in esophageal epithelial defense against acid

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

7 January 2021

CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

7 January 2021

Design, synthesis and evaluation of high-affinity binders for the celiac disease associated HLA-DQ2 molecule

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

7 January 2021

Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

7 January 2021

A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

7 January 2021

Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.77

7 January 2021